Literature DB >> 34988741

S184: preoperative sarcopenia is associated with worse short-term outcomes following transanal total mesorectal excision (TaTME) for rectal cancer.

Jeremy E Springer1, Catherine Beauharnais1, Derek Chicarilli2, Danielle Coderre3, Allison Crawford1, Jennifer A Baima3, Lacey J McIntosh2, Jennifer S Davids1, Paul R Sturrock1, Justin A Maykel1, Karim Alavi4.   

Abstract

INTRODUCTION: Malnutrition and deconditioning impact postoperative morbidity and mortality. Computed tomography (CT) body composition variables are used as markers of nutritional status and sarcopenia. The objective of this study is to evaluate the impact of sarcopenia, using CT variables, on postoperative outcomes following transanal total mesorectal excision (TaTME) for rectal cancer.
METHODS: This was an institutional retrospective cohort analysis of consecutive rectal cancer patients who underwent TaTME between April 2014 and May 2020. Psoas muscle index (PMI) was calculated from diagnostic CT scans. Based on previous studies, patients in the lowest PMI tertile by gender were considered sarcopenic. Fisher's exact and Mann-Whitney U test were used to compare categorical and continuous variables, respectively. Readmission rates and postoperative complications were compared between groups. Backward stepwise logistic regression was used to determine the association between sarcopenia and 30-day postoperative complications.
RESULTS: 85 patients were analyzed, of which 63% were male, with a median age of 59 (IQR: 51-65), and median BMI of 28 (IQR: 24-32). Of the entire cohort, 34% (n = 29) were sarcopenic (median PMI 5.39 IQR: 4.49-6.71). No significant difference in baseline characteristics between sarcopenic and nonsarcopenic patients were observed. 55% of sarcopenic patients experienced a complication within 30 days compared to 24% of nonsarcopenic patients (p = 0.01). 41% of sarcopenic patients required hospital readmission within 30 days compared to 17% of their nonsarcopenic counterparts (p = 0.014). Sarcopenic patients also experienced significantly higher rates of post-operative small bowel obstruction (10% vs. 0%, p = 0.04). Multivariable analyses identified that sarcopenic patients have a fourfold increase in odds of experiencing a 30-day postoperative complication (OR: 4.44, 95%CI: 1.6-12.4, p < 0.05) after adjusting for gender.
CONCLUSION: Preoperative sarcopenia is associated with increased 30-day postoperative complications following TaTME for rectal cancer. Postoperative complications can have serious oncologic implications by delaying adjuvant chemotherapy. Therefore, preoperative recognition of sarcopenia prior to undergoing TaTME for rectal cancer may provide an opportunity for early intervention with prehabilitation programs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Laparoscopy; Malnutrition; Rectal cancer; Sarcopenia; TaTME

Mesh:

Year:  2022        PMID: 34988741     DOI: 10.1007/s00464-021-08872-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  40 in total

1.  Incidence and Risk Factors for Anastomotic Failure in 1594 Patients Treated by Transanal Total Mesorectal Excision: Results From the International TaTME Registry.

Authors:  Marta Penna; Roel Hompes; Steve Arnold; Greg Wynn; Ralph Austin; Janindra Warusavitarne; Brendan Moran; George B Hanna; Neil J Mortensen; Paris P Tekkis
Journal:  Ann Surg       Date:  2019-04       Impact factor: 12.969

2.  A new solution to some old problems: transanal TME.

Authors:  R J Heald
Journal:  Tech Coloproctol       Date:  2013-03-22       Impact factor: 3.781

3.  A new approach to rectal cancer.

Authors:  R J Heald
Journal:  Br J Hosp Med       Date:  1979-09

4.  Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery.

Authors:  María Fernández-Hevia; Salvadora Delgado; Antoni Castells; Marta Tasende; Dulce Momblan; Gabriel Díaz del Gobbo; Borja DeLacy; Jaume Balust; Antonio M Lacy
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

Review 5.  Changing the Way We Manage Rectal Cancer-Standardizing TME from Open to Robotic (Including Laparoscopic).

Authors:  Katrina L Weaver; Leander M Grimm; James W Fleshman
Journal:  Clin Colon Rectal Surg       Date:  2015-03

Review 6.  Transanal Total Mesorectal Excision: A Novel Approach to Rectal Surgery.

Authors:  Pasithorn A Suwanabol; Justin A Maykel
Journal:  Clin Colon Rectal Surg       Date:  2017-04

7.  Transanal Total Mesorectal Excision for Rectal Cancer: Outcomes after 140 Patients.

Authors:  Antonio M Lacy; Marta M Tasende; Salvadora Delgado; María Fernandez-Hevia; Marta Jimenez; Borja De Lacy; Antoni Castells; Raquel Bravo; Steven D Wexner; Richard J Heald
Journal:  J Am Coll Surg       Date:  2015-03-30       Impact factor: 6.113

8.  Transanal Total Mesorectal Excision Versus Laparoscopic Surgery for Rectal Cancer Receiving Neoadjuvant Chemoradiation: A Matched Case-Control Study.

Authors:  Chien-Chih Chen; Yi-Ling Lai; Jeng-Kae Jiang; Chun-Ho Chu; I-Ping Huang; Wei-Shone Chen; Andy Yi-Ming Cheng; Shung-Haur Yang
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

9.  Short-term outcomes after transanal and laparoscopic total mesorectal excision for rectal cancer.

Authors:  A O Rasulov; Z Z Mamedli; S S Gordeyev; N A Kozlov; H E Dzhumabaev
Journal:  Tech Coloproctol       Date:  2016-01-21       Impact factor: 3.781

10.  Short-term Outcomes of Transanal versus Laparoscopic Total Mesorectal Excision: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Zhiyuan Wu; Wenlong Zhou; Fu Chen; Wentao Wang; Yong Feng
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.